Screener
Rein Therapeutics Inc. RNTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rein Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Rein Therapeutics Inc.’s 10-Q, filed May 15, 2026. Open the filing →
- Filed
- May 15, 2026, 7:56 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225352
FAQ
- What is Rein Therapeutics Inc.'s EPS (diluted)?
- Rein Therapeutics Inc. (RNTX) reported EPS (diluted) of -$0.19 in Q1 2026.
- How has Rein Therapeutics Inc.'s EPS (diluted) changed year-over-year?
- Rein Therapeutics Inc.'s EPS (diluted) increased by 24.0% year-over-year, from -$0.25 to -$0.19.
- What is the long-term trend for Rein Therapeutics Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Rein Therapeutics Inc.'s EPS (diluted) has grown at a -24.0% compound annual growth rate (CAGR), from -$5.88 to -$1.96.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Rein Therapeutics Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude